Company: TVRD
Filing Date: 2025-04-15
Form Type: 8-K
Source: 0001104659-25-035121
Chunk: 2

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-04-15
Form: 8-K
Item: Item 2.01
Chunk 2
---
 into an Asset Purchase Agreement (the “ APA”)
with Vifor Fresenius Medical Care Renal Pharma, Ltd., a majority-owned, indirect subsidiary of CSL Limited (“ CSL Vifor”),
pursuant to which, at the consummation of the transaction, Sellers sold to CSL Vifor and CSL Vifor acquired from Sellers certain assets
and rights for the development, manufacture and commercialization of difelikefalin as well as certain associated liabilities (the “ Asset
Disposition”) for a purchase price of $900,000 (subject to certain adjustments with respect to inventory). The Asset Disposition
closed on April 15, 2025.